Listed

Propanc Biopharma, Inc.: Form 10-Q for the period ended Dec 31, 2016

Filed with the SEC on Feb 14, 2017 and accepted by EDGAR at Feb 14, 2017, 12:58 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2016-10-01 to 2016-12-31$167.2kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2016-07-01 to 2016-12-31$328.4kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2016-10-01 to 2016-12-31−$1.9mus-gaap:OperatingIncomeLoss
Operating income6 months2016-07-01 to 2016-12-31−$3.1mus-gaap:OperatingIncomeLoss
Interest expense3 months2016-10-01 to 2016-12-31$1.3mus-gaap:InterestExpense
Interest expense6 months2016-07-01 to 2016-12-31$1.7mus-gaap:InterestExpense
Income tax3 months2016-10-01 to 2016-12-31$0us-gaap:IncomeTaxExpenseBenefit
Income tax6 months2016-07-01 to 2016-12-31$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2016-10-01 to 2016-12-31−$3.8mus-gaap:NetIncomeLoss
Net income6 months2016-07-01 to 2016-12-31−$4.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-10-01 to 2016-12-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2016-07-01 to 2016-12-31−$0.01us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2016-07-01 to 2016-12-31−$1.0mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure6 months2016-07-01 to 2016-12-31$0us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2016-12-31$42.9kus-gaap:Cash
Current assetsAt period end2016-12-31$122.5kus-gaap:AssetsCurrent
Total assetsAt period end2016-12-31$135.8kus-gaap:Assets
Current liabilitiesAt period end2016-12-31$4.0mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2016-12-31−$3.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-17-008493. Last ingested by Listed: Nov 14, 2026, 18:42 ET. Listed shows no prices and gives no investment advice.